CarboplatinÀ» Æ÷ÇÔÇÑ Ç×¾ÏÁ¦ Åõ¿©È¯ÀÚ¿¡¼ À¯¹ßµÈ ¿À½É, ±¸Åä¿¡ ´ëÇÑ palonosetron°ú ramosetronÀÇ Ç×±¸ÅäÈ¿°ú ºñ±³
A Comparison between Palonosetron and Ramosetron in Antiemetic Effect in Patients Administered with Carboplatin-containing Anticancer Drugs
º´¿ø¾à»çȸÁö 2010³â 27±Ç 4È£ p.392 ~ p.399
°í¿µÁÖ(Ko Young-Joo) - °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ¾àÁ¦ºÎ
ÀÌ¿¬Áö(Lee Yeon-Ji) - °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ¾àÁ¦ºÎ
ȲÀºÁ¤(Hwang Eun-jeong) - °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ¾àÁ¦ºÎ
³ªÇö¿À(La Hyen-O) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¾à¸®Çб³½Ç
Abstract
About 70 to 80% of patients who undergo chemotherapy experience chemotherapyinduced nausea and vomiting (CINV), which is one of the most common and important adverse events that affect the quality of life. Palonosetron, one of 5-HT3 receptor antagonists (5-HT3RAs), is used to prevent acute and delayed CINV as the only second-generation drug Between June and September 2009, 103 patients were administered with anticancer drugs containing carboplatin. Among them, patients with cervical, ovarian cancer and non-small cell lung cancer who were treated with carboplatin-paclitaxel or carboplatin-docetaxel, became the subjects of this study. This study was retrospectively performed, and the subjects were classified into two groups, the ramosetron group (R-Group; n=32) and the palonosetron group (P-Group; n=18). The two groups were compared to each other in antiemetic effect and cost. Patients who experienced CINV at least once accounted for 29% and 34% in P-Group and R-Group respectively. 50.9% of P-Group and 45.7% of R-Group took the additional antiemetic drugs. In relation to the cost of antiemetic drugs, P-Group costed a tenth part compared to R-Group.
Also, the cost of adding antiemetics above the drugs included in the regimen, P-Group costed 1/3 less compared to R-Group(p=0.004). In conclusion, palonosetron is as effective as the first-gen-eration of 5-HT3 RAs in frequency of emetogenicity. It is expected to be a useful antiemetic in the points of cost-effectiveness and ease of administration. However, this study was conducted on a small number of patients during a short period, thus it was problematic to evaluate the efficacies. A prospective study needs to be performed, excluding other factors that may influence
nausea and vomiting.
Å°¿öµå
palonosetron, ramosetron, nausea, vomiting, cost-effectiveness
KMID :
0869620100270040392
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
To prevent chemotherapyinduced nausea and vomiting (CINV), palonosetron is as effective as the first-gen-eration of 5-HT3 RAs in frequency of emetogenicity